Network materials which exhibit both shear thinning and self-healing properties are disclosed. The networks contain particles and gel-forming compounds. The networks are useful for a variety of biomedical uses, including drug delivery.

A product for preventing and treating external genitalia infection and/or flat warts is provided, wherein the product comprises a chloroquine nanosphere. The chloroquine nanosphere comprises a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative. A mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier during preparation ranges from 1:3 to 1:5. A loading rate of the chloroquine or the chloroquine derivative in the prepared chloroquine nanosphere ranges from 3.0% to 21.6%. The water-soluble nanosphere carrier is water-soluble chitosan; a deacetylation degree of the water-soluble chitosan ranges from 80% to 95%, and a viscosity-average molecular weight thereof ranges from 3000 to 5000 g/mol. The chloroquine derivative is selected from one or more of hydroxychloroquine, chloroquine phosphate or chloroquine sulfate.

A nanoparticulate composition including particles comprising at least one active ingredient, wherein the particles have an effective average particle size is in the range of about 70 nm to about 220 nm measured by laser light scattering method, wherein at least 50% of said active agent particles have a particle size, by weight (volume based), of less than the effective average particle size; and (b) at least one surface stabilizer and/or at least one polymeric stabilizer, wherein the composition includes (aa) particles of at least one active ingredient selected from the group consisting of (Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-(3-methyl-4-(trifluoromethyl)phenyl) prop-2-enamide, (Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]hept-2-en-6-ynamide, 2-cyano-3-cyclopropyl-N-(4-fluorophenyl)-3-hydroxyacrylamide, derivatives thereof, salts thereof and pro-drugs thereof, wherein the particles have an effective average particle size of less than about 2000 nm; and (bb) at least one surface stabilizer and/or at least one polymeric stabilizer.

Methods disclosed herein provide for an environmentally-friendly approach that employ citric extracts from fruits as unique reducing and stabilizing agents for making a tellurium nanomaterial. A particular method of making a tellurium nanomaterial includes combining citrus fruit extract with a tellurium salt to form a mixture of citrus fruit extract and dissolved tellurium salt; and heating the mixture of citrus fruit extract and dissolved tellurium salt, thereby making the tellurium nanomaterial. The resulting nanoparticles exhibit enhanced and desirable biomedical properties toward treatment of both infectious diseases and cancer.

Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).

The task of the invention is therefore making available transfer capsules that are taken up by the target cell type and permanently or transiently modify the target cell, without exerting any toxic effects on the cell during this process.

The solution according to the invention consists of the use of monodisperse cores, so as to produce polyelectrolyte nanocapsules having cell-specific sizes from them. The sizes for hematopoietic cells are in a range of 20-80 nm, preferably in a range of 40-60 nm. In this regard, the sizes of the particles must be in a very narrow range, so as to prevent toxic effects from occurring. In order to keep the toxicity of the nanocapsules low, it is furthermore important to remove the nanoparticles around which the capsules are built up (cores) before use. Methods in this regard are known from the state of the art (for example dissolution by means of EDTA).

A further task is the stabilization of the transfer capsules.

The solution according to the invention consists in the modification of the capsules, the layers and/or the cargo to be packed, by means of functional groups, which allows stabilization and thereby long-term storage at room temperature.

The third task is the targeted introduction of the transfer capsules.

The solution according to the invention is a functionalization of the layers by way of chemical modifications and/or supplementing of the layers with antibodies, proteins or peptides.

This disclosure presents compositions comprising phosphocreatine and nanoparticles containing triiodothyronine (T3), and to their use in treatment of cardiac conditions, particularly cardiac arrest and acute heart failure, as well as conditions generally relating to hypoxia, such as ischemia and stroke.

The present disclosure presents nanoparticle compositions for use in the treatment, prevention, or imaging of a disease (e.g., cancer), methods of treating, preventing, or imaging a disease in a subject in need thereof with the nanoparticle compositions, and methods of preparing the nanoparticle compositions of the disclosure. The nanoparticle compositions can include a magnetic nanoparticle ferric chloride, ferrous chloride, or a combination thereof, and a dextran coating functionalized with one or more amine groups.

Disclosed is a curcumin nanoparticle, including curcumin as core material and a wall material, where a weight ratio of the curcumin to the wall material is (5.5-7.5):100, and the wall material includes gum arabic and zein in a weight ratio of (1-5):5. The disclosure further provides a method of making the curcumin nanoparticle and a curcumin beverage containing the curcumin nanoparticle.

Compositions that increase the bioavailability of dihydromyricetin are presented. The bioavailability is increased by methods including formulating dihydromyricetin in nanoparticle form, delivering dihydromyricetin with permeabilizers, and encapsulating dihydromyricetin with an enteric coating.